Open an account

Ionis Pharmaceuticals

IONS · NASDAQ

$45.40+$1.02 (+2.30%)TodayMarket closed ·
Prev close $44.38

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Employees
1,402
Headquarters
Carlsbad, California
Listed
May 17, 1991
Sector
Health Care
Industry
Biotechnology
Website
ionis.com

IONS key statistics

Market cap
7.54B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.31M
Volume
2.49M
Open price
$44.45
High today
$45.48
Low today
$44.01
52 Week high
$86.74
52 Week low
$42.08

Ionis Pharmaceuticals (IONS) at a glance

Ionis Pharmaceuticals (IONS) last traded at $45.40, with a market cap of 7.54B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $44.01 and $45.48. The current price is 3.2% above the day's low and 0.2% below its high.

Volume so far is 2.49M shares, below the average of 3.31M shares a day.

Over the past year Ionis Pharmaceuticals has ranged from $42.08 to $86.74, and now sits 7% of the way up that range.

Ionis Pharmaceuticals met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.69 per share against an estimate of -$1.09.

The average analyst price target is $86.07, 89.6% above the current price, from 22 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

82%of 22 analyst ratings say Buy
  • Buy81.8%
  • Hold18.2%
  • Sell0.0%
Price target · 25 analystsAvg $86.07
Low
$54.54
Now
$45.40
High
$110.25

IONS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 64.7% on average.

  1. Q3 FY24: reported -$0.95 per share against an estimate of -$1.18
  2. Q4 FY24: reported -$0.66 per share against an estimate of -$1.15
  3. Q1 FY25: reported -$0.93 per share against an estimate of -$1.14
  4. Q2 FY25: reported $0.70 per share against an estimate of -$0.4387
  5. Q3 FY25: reported -$0.80 per share against an estimate of -$1.26
  6. Q4 FY25: reported -$1.41 per share against an estimate of -$1.35
  7. Q1 FY26: reported -$0.56 per share against an estimate of -$0.9283
  8. Q2 FY26: reported -$0.69 per share against an estimate of -$1.09

IONS news

  • Press releaseBusiness Wire

    TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

  • Vandana Singh

    Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease

  • Press releaseBusiness Wire

    Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

  • Vandana Singh

    Ionis to Seek Expedited FDA Review for ALS Drug

  • Chandrima Sanyal

    Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

  • Press releaseBusiness Wire

    Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

  • Kaustubh Bagalkote

    Why Is Eli Lilly Stock Falling Tuesday?

  • Avi Kapoor

    Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Similar companies

Companies in the same industry as Ionis Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.